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ABSTRACT
Objective To evaluate the dynamics and longevity of the 
humoral immune response to SARS- CoV-2 infection and 
assess the performance of professional use of the UK- 
RTC AbC-19 Rapid Test lateral flow immunoassay (LFIA) 
for the target condition of SARS- CoV-2 spike protein IgG 
antibodies.
Design Nationwide serological study.
Setting Northern Ireland, UK, May 2020–February 2021.
Participants Plasma samples were collected from a 
diverse cohort of individuals from the general public 
(n=279), Northern Ireland healthcare workers (n=195), 
pre- pandemic blood donations and research studies 
(n=223) and through a convalescent plasma programme 
(n=183). Plasma donors (n=101) were followed with 
sequential samples over 11 months post- symptom onset.
Main outcome measures SARS- CoV-2 antibody levels 
in plasma samples using Roche Elecsys Anti- SARS- CoV-2 
IgG/IgA/IgM, Abbott SARS- CoV-2 IgG and EuroImmun IgG 
SARS- CoV-2 ELISA immunoassays over time. UK- RTC AbC-
19 LFIA sensitivity and specificity, estimated using a three- 
reference standard system to establish a characterised 
panel of 330 positive and 488 negative SARS- CoV-2 IgG 
samples.
Results We detected persistence of SARS- CoV-2 IgG 
antibodies for up to 10 months post- infection, across 
a minimum of two laboratory immunoassays. On the 
known positive cohort, the UK- RTC AbC-19 LFIA showed a 
sensitivity of 97.58% (95.28% to 98.95%) and on known 
negatives, showed specificity of 99.59% (98.53 % to 
99.95%).
Conclusions Through comprehensive analysis of a cohort 
of pre- pandemic and pandemic individuals, we show 
detectable levels of IgG antibodies, lasting over 46 weeks 
when assessed by EuroImmun ELISA, providing insight 
to antibody levels at later time points post- infection. We 
show good laboratory validation performance metrics for 
the AbC-19 rapid test for SARS- CoV-2 spike protein IgG 
antibody detection in a laboratory- based setting.
INTRODUCTION
The WHO declared a pandemic in March 
2020 due to SARS- CoV-2, identified in late 
2019 in Wuhan, China, causing COVID-19 
disease.1 2
Strengths and limitations of this study
 ► This paper describes a non- clinical laboratory evalu-
ation and comparison of the ability of three different 
immunoassays to detect SARS- CoV-2 antibodies in 
the same samples, detecting different subtypes of 
antibodies against different targets of the viral anti-
genic repertoire that does not rely on PCR positivity 
as definition of expected test outcome, to provide 
a panel of known antibody positive and antibody 
negative serology for evaluation of newly developed 
immunoassays.
 ► This study demonstrates AbC-19 lateral flow point- 
of- care detection of IgG antibodies to the full trimeric 
spike protein of SARS- CoV-2 virus, the antibodies 
made in response to the vaccines used globally, in a 
large cohort of subjects, more than 10 months post- 
infection, across a broad age range (18–78 years).
 ► This study assesses correlation between approved 
laboratory- based assays and the AbC-19 lateral 
flow point- of- care lateral flow test for the detection 
of SARS- CoV-2 antibodies in characterised cohorts 
of known positive and negative plasma samples in 
an evaluation conducted according to Medicines and 
Healthcare products Regulatory Agency guidelines 
during a pandemic.
 ► Longitudinal data detecting IgG antibodies more 
than 10 months from infection were collected as se-
quential samples over time through a convalescent 
plasma donation programme.
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A global race ensued to develop diagnostic assays, with 
the most common being viral RNA detection (reverse 
transcription- quantitative PCR (RT- qPCR) assays), to 
detect acute infection.3 RT- qPCR assays are labour and 
reagent intensive, limited by a short temporal window for 
positive diagnosis, and exhibit potential for false nega-
tive results.4 Evidence suggests sensitivity of RT- qPCR can 
be as low as 70%.5 False positive rates between 0.8% and 
4.0% have been reported in the UK and are dependent 
on the cycle threshold values accepted as indicating infec-
tion, the number of SARS- CoV-2 genes analysed and the 
proportion of asymptomatic individuals tested.6 7 Lock-
down measures and ‘flattening the curve’ strategies in 
the UK meant many infected individuals were instructed 
to self- isolate and were not offered a diagnostic RT- qPCR, 
with much of the testing limited to patients admitted to 
hospital, who perhaps reflect a more severely infected 
cohort. Consequently, a potentially large number of cases 
were unconfirmed or undetected.8
The ability to accurately detect SARS- CoV-2 specific 
antibodies, which develop after an immune response is 
evoked, is vital for building biobanks of convalescent sera 
for treatment, monitoring immune response to infection 
alongside surveillance studies and assessing responses to 
vaccination programmes.
Commercial serology immunoassays are mostly labora-
tory based and measure IgG antibody levels in plasma or 
serum. Alternatively, lateral flow immunoassays (LFIAs) 
require a finger prick blood sample and can be used at 
point- of- care (POC) or in the home; particularly important 
in the context of lockdown enforcement during the 
pandemic. A limited number of laboratory- based chemi-
luminescence immunoassays are approved for use in the 
UK including the Roche Elecsys Anti- SARS- CoV-2 IgG/
IgA/IgM against the SARS- CoV-2 Nucleocapsid antigenic 
region (Roche Diagnostics, Basel, Switzerland) and the 
Abbott SARS- CoV-2 IgG assay against the same antigenic 
region (Abbott Diagnostics, Abbott Park, Illinois, USA).
The complexities of the humoral immune response 
to SARS- CoV-2 are a much- debated topic. In a US study, 
approximately 1 in 16 individuals lacked detectable IgG 
antibodies up to 90 days post- symptom onset, despite 
previous RT- qPCR- confirmed infection.9 Patients who 
remain asymptomatic may mount a humoral immune 
response which is short lived, with detectable levels of anti-
body falling rapidly.10 This, alongside the lack of RT- qPCR 
test availability across the UK, has hindered the develop-
ment of a well- characterised gold standard serology test 
for IgG antibodies to SARS- CoV-2.
Herein, we describe the use of Roche and Abbott 
commercial immunoassays, as well as the EuroImmun 
Anti- SARS- CoV-2 ELISA- IgG against the S1 domain of the 
spike (antigenic) protein of SARS- CoV-2 (EuroImmun 
UK, London, UK) to characterise pre- pandemic and 
pandemic COVID-19 blood samples (n=880) from within 
Northern Ireland and report on longevity of IgG anti-
bodies detected. Furthermore, we follow IgG antibody 
levels in convalescent plasma donors (n=101 individuals) 
for up to 11 months. Currently, there is no gold stan-
dard assay for comparison, therefore we aimed to estab-
lish a reference based on a positive COVID-19 antibody 
status. We present results of a laboratory evaluation of 
the UK- RTC AbC-19 with a target condition of antibodies 
against a cohort of 330 known IgG antibody positive 
samples according to this ‘positive by two’ system and 488 
negative samples (223 pre- pandemic assumed negative 
and 265 known negative) for IgG to SARS- CoV-2.
METHODS
Participant samples
The flow of participant samples is summarised in online 
supplemental figure 1. A small cohort (n=19) of anony-
mised plasma samples were obtained from a partner USA 
laboratory for initial protocol development only. All partic-
ipants provided informed consent. An online recruitment 
strategy was employed, with the study advertised through 
internal Ulster University email, website and social media. 
A BBC Newsline feature providing the pandemic study 
email address also prompted interest from the general 
population. The first 800 respondents who expressed 
interest were provided with an online patient information 
sheet, consent form and health questionnaire and invited 
to register to attend a clinic. Participants were eligible 
for the study if they were over 18 years of age. Exclusion 
criteria included anyone with a blood disorder or contra-
indication to giving a blood sample, or anyone currently 
exhibiting symptoms of COVID-19. To enrich the cohort 
for samples potentially positive for SARS- CoV-2 IgG anti-
body, further participants were invited if they had previ-
ously tested PCR positive or had the distinctive symptom 
of loss of taste and smell. Blood sampling clinics were 
held at locations around Northern Ireland between May 
and July 2020 resulting in collection of 263 10 mL EDTA 
plasma samples from 263 separate study participants. 
Additional anonymised plasma samples were obtained 
from Southern Health and Social Care Trust (SHSCT) 
healthcare workers (n=195) and Northern Ireland Blood 
Transfusion Service (NIBTS, n=184) through convales-
cent plasma programmes. NIBTS convalescent plasma 
samples continued to be collected throughout 2020–
early 2021, with a total of n=897 from n=676 individuals, 
including n=183 samples from the cross- sectional cohort. 
Individuals from this programme with a positive RT- qPCR 
Strengths and limitations of this study 
 ► This study was conducted in a standardised setting with very expe-
rienced users on plasma characterised as positive or negative for 
the presence of antibodies using a reference standard, alongside 
one other assay which may introduce a possible spectrum bias and 
may not reflect the true performance metrics of the assay evalu-
ated when translated to real- life settings, using finger prick blood 
samples and in which pretest probability would impact greatly on 
positive and negative predictive values.









pen: first published as 10.1136/bm




3Robertson LJ, et al. BMJ Open 2021;11:e048142. doi:10.1136/bmjopen-2020-048142
Open access
result and EuroImmun starting value >6 were sequentially 
sampled over a period of up to 46 weeks resulting in a 
cohort of n=101 individuals, n=296 samples (including 
n=47 individuals from the cross- sectional cohort).
Pre- pandemic samples (prior to June 2019, n=136) 
were obtained from Ulster University Ethics Committee- 
approved studies with ongoing consent and from NIBTS 
(n=200, more than 3 years old). Plasma samples were used 
at no more than three freeze–thaw cycles for all analyses 
reported within this manuscript.
Clinical information
Basic demographic information and data with regard to 
probable or definite prior infection with SARS- CoV-2 were 
obtained from PANDEMIC Study participants through 
the secure online questionnaire requiring responses 
about positive RT- qPCR result and/or time from symptom 
onset. Anonymised participant samples from the USA, 
SHSCT and NIBTS were provided with age, gender and 
time since PCR positive, where a previous test had been 
carried out.
Laboratory-based immunoassays
Details of laboratory immunoassays are summarised in 
online supplemental methods and online supplemental 
table 1.
UK-RTC AbC-19 LFIA
All analyses were performed on UK- RTC AbC-19 Tech-
nical Transfer 3 devices at Ulster University according 
to manufacturer’s instructions (details in online supple-
mental table 1). Assays were performed as cohorts, with 
samples in batches of 10, with one researcher adding 
2.5 µL of plasma to the assay and a second adding 100 µL 
of buffer immediately following sample addition. After 
20 min, the strength of each resulting test line was scored 
from 0 to 10 according to a visual score card (scored by 
three researchers; online supplemental figure 2). A score 
≥1 was positive. Details of samples used for analysis for 
detection of antibodies are available in online supple-
mental methods.
Statistical analysis
As per Daniel,11 a minimum sample size based on prev-






d2  , where n=sample size, Z=Z statistic for a 
chosen level of confidence, P=estimated prevalence and 
d=precision. Assuming a prevalence of SARS- CoV-2 of 
10% and a precision of 5%, we estimate that the required 
sample size at 99% confidence (Z=2.58) to be 240 indi-
viduals. If the true prevalence is lower, 5%, the estimated 
required sample size given a precision of 2.5% is 506 indi-
viduals. A minimum sample size of 200 known positives 
and 200 known negatives is given within Medicines and 
Healthcare products Regulatory Agency guidelines for 
SARS- CoV-2 LFIA antibody immunoassays.12
Statistical analysis was conducted in in R V.4.0.2.13 To 
assess discordance between test results, data were first 
filtered to include individuals with an Abbott test result 
in the range ≥0.25–≤1.4, with a 2×2 contingency table 
produced that comprised all possible combinations of 
(concordant|discordant) test results (within|outside) of 
this range. A p value was derived via a Pearson χ2 test after 
2000 p value simulations via the stats package.
AbC-19 LFIA performance analyses were performed 
using MedCalc online (MedCalc Software, Ostend, 
Belgium). Receiver operating characteristic curve analysis 
was performed via the pROC package. To compare test 
result (positive|negative) with age, a binary logistic regres-
sion model was produced with test result as outcome—a 
p value was then derived via χ2 analysis of variance. To 
compare time against test result (encoded continuously), 
a linear regression was performed. We calculated median 
per time period and then converted these to log (base 2) 
ratios against the positivity cut- off for each assay. All plots 
were generated via ggplot2 or custom functions using 
base R.14
RESULTS
We analysed samples from a mixed cohort of individ-
uals from the general public (n=279), Northern Ireland 
healthcare workers (n=195), pre- pandemic blood dona-
tions and research studies (n=223), and through a conva-
lescent plasma programme (n=183). Antibody levels in 
plasma from these 880 individuals were assessed using 
the three SARS- CoV-2 immunoassays: EuroImmun IgG, 
Roche Elecsys IgG/IgM/IgA and Abbott Architect IgG 
(online supplemental table 1 and online supplemental 
figure 3). This included a cohort of 223 pre- pandemic 
plasma samples collected and stored during 2017 to end 
of May 2019 to determine assay specificity. Of the 657 
participants whose samples were collected during the 
pandemic, 267 (40.64%) previously tested RT- qPCR posi-
tive with a range of 7–173 days since diagnosis. A total of 
225 participants gave time since self- reported COVID-19 
symptoms, with a range of 5–233 days from symptom 
onset, while 195 had no symptom or PCR data available. 
Samples collected in 2020 (n=657) ranged from 19 to 78 
years of age with a median (IQR) of 43 years (±22), and 
n=454 were women and n=200 men (n=3, not disclosed). 
Pre- pandemic samples (n=223) ranged from 20 to 87 
years of age with median (IQR) of 50 years (±20) and 
consisted of n=88 women and n=135 men.
Laboratory-based antibody immunoassays
A positive result for antibody on one or more of the 
three laboratory immunoassays was recorded for 385 of 
657 (58.6%) participants who provided a sample during 
the pandemic. By EuroImmun ELISA, 346 were positive, 
20 borderline and 291 were negative. The Roche assay 
detected 380 positive and 277 negative, while Abbott 
determined 310 positive and 347 negative (online 
supplemental table 2 and online supplemental figure 
3). The median age across all age groups combined 
was lower for participants testing positive across each of 
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the immunoassays (median (SD) for positive vs nega-
tive, respectively: EuroImmun, 41 (13.16) vs 48 (12.95); 
Roche, 42 (13.08) vs 48 (13.00); Abbott, 41 (13.18) vs 47 
(13.09)) (online supplemental figure 4, p<0.0001). When 
segregated by age group, however, differences were less 
apparent in certain groups (online supplemental figure 
5). Excluding the pre- pandemic cohort, this gap reduced 
but remained statistically significant: EuroImmun, 41 
(13.18) vs 45 (12.49); Roche, 42 (13.15) vs 45 (12.49); 
Abbott, 41 (13.26) vs 44 (12.63) (p<0.01) (median (SD) 
for positive vs negative). Of note, out of 267 individuals 
with a previous positive RT- qPCR result for SARS- CoV-2 
viral RNA, 14 (5.2%, online supplemental figure 3A) did 
not show detectable antibodies by any of the three immu-
noassays, with no association found with age, gender or 
time between test and blood draw (data not shown).
The three commercial laboratory immunoassays 
provide a ratio value that increases with IgG antibody 
titre. When correlation between these values is assessed, 
good overall agreement is observed between the three 
immunoassays (figure 1A–C and online supplemental 
figure 9). As highlighted by Rosadas et al,15 we also see 
significant disagreement in the Abbott 0.25–1.4 range 
when compared with EuroImmun and Roche (figure 1; 
Χ2 p values: EuroImmun vs Abbott, p<0.001; Roche vs 
Abbott, p<0.001).
Duration of humoral response to SARS-CoV-2
In a cross- sectional analysis of antibodies over time, we 
found IgG antibodies could still be detected in individuals 
(excluding pre- pandemic) across all three immunoassays 
used up to week 20 (day 140) (figure 2). We note a statis-
tically significant decrease in signal with respect to time 
across each assay (p value (estimate slope)): EuroImmun, 
p=0.028 (−0.823); Roche, p=0.002 (−0.125); Abbott, 
p<0.0001 (−3.673). These remained statistically signifi-
cant after adjustment for age. Antibody levels (expressed 
as a ratio of median result per time point divided by posi-
tivity cut- off; table 1) peaked at week 1–2 for EuroImmun 
(1.33) and Abbott (1.64), though reached highest levels 
at week 9–12 when measured by Roche (5.45). By week 
21–24, median score for all tests had dropped below 
the positivity cut- off, though a small number of samples 
remained above the positive cut- off at these later time 
points (figure 2).
Samples from the NIBTS convalescent plasma 
programme continued to be collected throughout 2020–
early 2021. A total of n=897 samples from n=676 indi-
viduals were collected, 744 of 883 tested by EuroImmun 
were positive (>1.1, with values range of 0.051–34.361), 
556 of 749 tested by Abbott were positive (>1.4, with 
values ranging from 0.01 to 8.85). Individuals with a posi-
tive RT- qPCR result and a EuroImmun result >6 were 
sequentially sampled (with median 3, range 2–9 samples 
per individual), and analysed by both EuroImmun 
(n=101 individuals) and Abbott immunoassays (n=75 
individuals). Median age (IQR) for this cohort is 51 years 
(±21) with a range from 18 to 70 years and n=27 women, 
n=74 men. Longitudinal analysis shows persistence of 
detectable IgG antibodies until up to 302 days (43 weeks) 
by Abbott immunoassay (at which point this assay was 
discontinued at NIBTS) and 323 days (46 weeks) by Euro-
Immun ELISA, with a gradual decline over time (online 
supplemental figure 6). None of the individuals who were 
initially positive by EuroImmun SARS- CoV-2 S1 IgG assay 
dropped to below the EuroImmun positivity threshold 
(>1.1) over the course of the follow- up, while 26 who were 
initially positive by Abbott SARS- CoV-2 NP IgG fell below 
the Abbott threshold (>1.4).
UK-RTC AbC-19
Using the commercial immunoassays described, we 
established a well- characterised serology sample set of 









































Fit lines, LOESS with 95% CI
Vertical lines mark Abbott test range 0.25−1.4
A) B) C)
Figure 1 Two- way correlation scatter plots comparing (A) EuroImmun, (B) Abbott and (C) Roche immunoassays. Pearson 
χ2 test was used to assess correlations. The results for each test were log transformed to ensure results follow a normal 
distribution. Negative agreement shown as blue dots, red dots show positive agreement for the two immunoassays, while black 
dots show disagreement and grey dots as the EuroImmun borderline results. Vertical lines mark the Abbott test range 0.25–1.4. 
n=880. The graphs show positive correlations between all immunoassays evaluated, with the fewest disagreement of results 
between the log of Roche and the log of EuroImmun. Fit lines locally estimated scatterplot smoothing (LOESS), with 95% CI 
shaded.
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to SARS- CoV-2 to evaluate performance metrics for the 
UK- RTC AbC-19 Rapid LFIA.
AbC-19 detects IgG antibodies against the spike protein 
antigen, so we therefore required all samples to be posi-
tive by the EuroImmun SARS- CoV-2 IgG ELISA, which 
likewise detects antibodies against the S1 domain.16 To 
develop this characterised cohort, samples were also 
required to be positive by a second immunoassay (Roche 
or Abbott). To analyse specificity of the AbC-19 LFIA 
for detection of SARS- CoV-2 IgG antibody, we assessed 
350 plasma samples from participants classed as ‘known 
negative for SARS- CoV-2 IgG antibody’ on the AbC-19 
LFIA. All samples were from individuals confirmed to be 
negative across all three laboratory assays (Roche, Euro-
Immun, Abbott). Using these positive n=304 and negative 
n=350 antibody cohorts, we determined a sensitivity for 
detecting SARS- CoV-2 IgG antibody of 97.70% (95% CI: 
95.31% to 99.07%) and specificity of 100% (98.95% to 
100.00%) for the AbC-19 LFIA (table 2).
Given a recent report of lower specificity in the AbC-19 
LFIA17 and the possibility of introducing sample bias, we 
revised our inclusion criteria for the negative cohort. For 
the pre- pandemic cohort, we included samples from all 























































































Figure 2 SARS- CoV-2 antibody levels by (A) EuroImmun, (B) Roche and (C) Abbott, relative to weeks since first reported 
symptoms or positive PCR result (where data available, n=685). RT- PCR- positive individuals are denoted by red dots, while 
individuals with time since symptom data are denoted in black. Dashed lines delineate loge equivalent of positivity threshold 
(EuroImmun 1.1, Roche 1.0, Abbott 1.4) for each test, and the negativity threshold for EuroImmun (0.8; borderline result between 
the two lines). Black bars indicate median, within IQR boxes for EuroImmun/Roche/Abbott value. Red triangles indicate outliers, 
based on 1.5×IQR. RT- PCR, reverse transcription- PCR.









pen: first published as 10.1136/bm




6 Robertson LJ, et al. BMJ Open 2021;11:e048142. doi:10.1136/bmjopen-2020-048142
Open access 
immunoassays. When this assumed negative pre- pandemic 
cohort was used for laboratory evaluation for target condi-
tion of antibodies, we observed a specificity of 99.55% 
(97.53% to 99.99%, table 2). We expanded the negative 
cohort to include all samples that matched our criteria 
(samples collected during the pandemic to be negative by 
all three laboratory assays and all pre- pandemic samples 
regardless of other immunoassay results). The specificity 
observed on this extended negative cohort of 488 samples 
was 99.59% (98.53% to 99.95%, table 2). For sensitivity 
analysis on a positive cohort (samples positive by Euro-
Immun and one other test), we were able to analyse 
all samples previously untested due to limited testing 
capacity and tested a positive cohort of 330 samples giving 
a sensitivity of 97.58% (95.28% to 98.95%, table 2). When 
we sorted samples analysed in both negative (n=488) and 
positive cohorts (n=330) by RT- qPCR status and assessed 
AbC-19 LFIA sensitivity by including only those that were 
RT- qPCR positive (n=227), the test showed a sensitivity of 
92.07% (87.76% to 95.23%; online supplemental table 
3 and online supplemental figure 3B). However, of the 
n=18 RT- qPCR- positive individuals negative for IgG anti-
bodies by AbC-19, n=12 showed no detectable antibodies 
by all three laboratory assays (EuroImmun, Roche or 
Abbott), suggesting that antibodies are not present in 
those samples (online supplemental figure 3C).
When used as intended by the public, the AbC-19 LFIA 
provides binary positive/negative results. However, when 
assessing LFIA in the laboratory, each test line was scored 
against a scorecard by three independent researchers 
(0 negative, 1–10 positive; online supplemental figure 
2). When compared with quantitative outputs from the 
Abbott, EuroImmun and Roche assays, the AbC-19 LFIA 
shows good correlation (Abbott r=0.84 (p<0.001); Euro-
Immun r=0.86 (p<0.001); Roche r=0.82 (p<0.001); online 
supplemental figures 3 and 7–9).
Analytical specificity and sensitivity of AbC-19 LFIA
We observed no cross- reactivity across samples with 
known H5N1 influenza, respiratory syncytial virus, influ-
enza A, influenza B, Bordetella pertussis, Haemophilus influ-
enzae, seasonal coronavirus NL63 and 229E on the AbC-19 
LFIA (n=34 samples, n=8 distinct respiratory viruses; 
online supplemental table 4). Against a panel of external 
reference SARS- CoV-2 serology samples, the AbC-19 LFIA 
detected antibodies with scores commensurate to the 
EuroImmun ELISA scores (online supplemental figure 
10 and online supplemental table 5).
DISCUSSION
Serological antibody immunoassays are an important 
tool in helping combat the SARS- CoV-2 pandemic. The 
duration of the humoral immune response is of partic-
ular importance, to inform an individual’s protection 
following both natural infection and vaccination. Using a 
Table 1 Antibody level ratios for assays over time
Ratio median antibody level: assay positivity cut- off
                            Week
  Pre-2020 1–2 3–4 5–8 9–12 13–16 17–20 21–24 25–28 29+
EuroImmun −2.65 1.33 0.2 0.95 1.32 0.47 0.04 −2.01 −2.26 −2.01
Roche −3.64 3.16 3.05 5.20 5.45 4.14 4.42 −3.54 −3.69 −3.61
Abbott −5.54 1.64 −0.51 1.12 0.86 0.08 −0.59 −5.13 −5.13 −6.13
Sample number (n=) 223 20 10 52 90 202 53 11 12 11
Antibody level ratios for assays over time show varying peak levels depending on test. Calculated by first establishing the median per time 
period, then calculating log2 ratio for each period versus each respective assay positivity cut- off.


















223 222 1 n/a n/a n/a n/a 99.55 (97.53 to 99.99)
Initially reported cohorts (n=654)









LFIA, lateral flow immunoassay; n/a, not available.
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large cohort of individuals across a wide age range (18–78 
years), we assessed antibody levels across up to three labo-
ratory immunoassays and perform a cross- sectional and 
longitudinal analysis over time. Our results show strong 
correlation between all three immunoassays, with short-
comings in the Abbott system output 0.25–1.4 range, as 
described previously, suggesting an overestimated posi-
tive cut- off (figure 1).15
Longitudinal studies on SARS- CoV-1 convalescent 
patients suggest that detectable IgG can still be present 
as long as 2 years after infection.18 There are conflicting 
reports of the longevity of the humoral response to 
SARS- CoV-2 infection which differ in the make- up of the 
cohort studied, the assays used and the length of time since 
symptom onset. The longevity of IgG antibodies to both 
spike and nucleocapsid protein more than 10 months after 
RT- qPCR- positive status (and beyond in a small number 
of samples (figure 2 and online supplemental figure 6) is 
consistent with that observed in other recent studies.19–21 
In this study, samples were collected through a conva-
lescent plasma programme (online supplemental figure 
6), with individuals selected for sequential plasma dona-
tion based on an initial high EuroImmun assay score. In 
contrast to the time series analysis of healthcare workers 
recruited prospectively by Manisty et al,22 we observed 
no cases where EuroImmun ELISA- measured anti- spike 
antibody levels fell below threshold, while a large number 
of Abbott measured anti- nucleocapsid antibody levels 
dropped below the positivity threshold (34.7%, 26 of 75). 
However, this may be an overestimate given the short-
comings of the Abbott assay described above (figure 1). 
In a similar longitudinal study of 51 symptomatic partici-
pants, Dan et al estimated that half- life (t1/2) for IgG- spike 
(103 days) was longer than that for IgG- nucleocapsid (68 
days), although with a considerable overlap of 95% CIs.23
In our more diverse cross- sectional cohort, we also 
note a statistically significant decline over time but levels 
remain detectable at 140 days (figure 2). We note that IgG 
levels reach their peak (Roche ratio 5.45 times threshold 
cut- off) as late as week 9–12 from first symptoms or a 
viral RNA RT- qPCR positive result, though this may be an 
artefact of lower number of participants at earlier time 
points (table 1). Robust antibody responses are produced 
in our cohorts across a wide age range (18–78 years old, 
figure 2 and online supplemental figure 6). We detect a 
slightly but significantly lower median age of participants 
testing positive (online supplemental figure 4); however, 
this is likely be due to cohort characteristics and not a 
true reflection of the population or indication of test 
performance.
A difficulty faced in validation of antibody diagnostic 
assays has been access to samples with known SARS- CoV-2 
antibody status. As previously described, there is no clear 
gold standard reference against which to assess SARS- CoV-2 
immunoassays. A positive RT- qPCR test has been used 
previously to indicate previous (COVID-19) SARS- CoV-2 
infection, though this approach is limited by a high rate 
of false negatives and positives in RT- qPCR testing, failure 
in some cases to develop IgG antibodies (sero- silence 
or lack of antibody against the same antigenic compo-
nent of the virus as the immunoassay used as a capture 
antigen) and the lack of RT- qPCR testing availability early 
in the pandemic.3 5 24 SARS- CoV-2 IgG antibodies were 
undetectable in 14 of 267 (5.2%) of previously RT- qPCR 
SARS- CoV-2 viral RNA- positive participants in this study. 
It is unclear if this is due to insufficient/absent antibody 
production in these individuals at the time the sample 
was taken, or due to a false positive PCR result which may 
occur in the UK at a rate between 0.8% and 4.0%.6 Self- 
assessment of symptoms for COVID-19 (disease) is a poor 
indicator of previous infection, even among healthcare 
workers.25 Additionally, the kinetics of a SARS- CoV-2 virus 
infection contributes to the loss of sensitivity of RT- qPCR 
to detect virus with time, contributing to false negative 
RT- qPCR test results for individuals who may be late to 
present for virus detection tests.5 26
To assess sensitivity and specificity of the AbC-19 LFIA 
for its ability to detect SARS- CoV-2 antibody in a labora-
tory evaluation, we developed a reference standard for 
SARS- CoV-2 antibodies, which does not rely on a single 
test as reference. A similar approach was used in a recent 
seroprevalence study in Iceland, whereby two positive 
antibody results were required to determine a participant 
sample as positive for SARS- CoV-2 antibody.24 Our eval-
uation of performance metrics for the UK- RTC AbC-19 
LFIA to detect antibodies for SARS- CoV-2 gave 97.58% 
sensitivity and 99.59% specificity. In an evaluation of the 
AbC-19 tests, Mulchandani et al observed a specificity of 
97.9% (97.2% to 98.4%) in a cohort of pre- pandemic 
samples and report a sensitivity of 92.5% (88.8% to 95.1%) 
for detecting previous infections (based on a previous 
RT- qPCR result) or 84.7% (80.6% to 88.1%) against the 
Roche Elecsys antibody test, which detects IgM/IgG/IgA 
SARS- CoV-2 antibodies to the nucleocapsid portion of 
SARS- CoV-2.25 In RT- qPCR- positive individuals from our 
cohorts, the AbC-19 test showed a similar sensitivity of 
92.07% (87.76% to 95.23%, online supplemental figure 
3, online supplemental table 3). However, we demon-
strate the drawbacks of this approach given that in 12 of 
18 AbC-19 false negatives, none of the four immunoassays 
used (EuroImmun, Roche, Abbott or AbC-19) detected 
antibodies, suggesting either a false RT- qPCR result, a 
failure to produce IgG antibodies or sero- reversion before 
sample collection in these individuals. Another recent 
evaluation of the AbC-19 LFIA by Moshe et al27 determined 
a sensitivity of 100% (98.1% to 100%) on laboratory sera, 
using a composite reference standard of antibody positive 
by either spike protein ELISA or hybrid double antigen 
binding assay (DABA) and specificity of 99.8% (98.9% 
to 100%) against pre- pandemic samples. However, when 
AbC-19 performance was analysed on matched finger 
prick and serum samples against the same antibody stan-
dard, a lower sensitivity was observed (finger prick 69% 
(53.8% to 81.3%), serum 92% (80% to 97.7%)).
In our study, strong correlation was observed in quan-
titative score between results on all immunoassays with 
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the highest observed between EuroImmun and AbC-19 
LFIA (online supplemental figures 8 and 9). This is to be 
expected, given both the AbC-19 LFIA and EuroImmun 
ELISA detect IgG antibodies against spike protein. Impor-
tantly, for the assessment of immunity to prior natural 
infection as well as to immunisation, IgG antibodies 
against SARS- CoV-2 spike protein detected by laboratory- 
based EuroImmun ELISA and AbC-19 LFIA are known to 
correlate with neutralising antibodies, which may confer 
future immunity.23 28 29 Previous evaluations of sensitivity 
and specificity reported by Public Health England (PHE) 
showed a EuroImmun sensitivity of 72% and specificity 
of 99%, Abbott with sensitivity of 92.7% and specificity of 
100%, and Roche with sensitivity of 83.9% and specificity 
of 100%.30–32 The PHE analyses for each of these tests 
used previous infection (RT- qPCR- positive status) as a 
reference standard, the limitations of which are discussed 
above.
In the use of characterised ‘known positive’ and ‘known 
negative’ cohorts, one limitation of this study is its poten-
tial for spectrum bias, whereby our positive by two refer-
ence system may artificially raise the threshold for positive 
sample inclusion, possibly resulting in the overestimation 
of the sensitivity of any test evaluated.33 However, similar 
issues have been raised when using previous RT- qPCR 
result or definitive COVID-19 symptoms as inclusion 
criteria given these will likely skew a cohort towards 
more severe disease, especially given issues of RT- qPCR 
availability outside of hospital settings during the first 











































Figure 3 AbC-19 extended cohort (n=818) correlation to (A) EuroImmun, (B) Roche and (C) Abbott scores. Box plots overlaid 
on scatter plot, comparing AbC-19 TT3 test scores with EuroImmun, Roche and Abbott quantitative antibody values. Red linear 
line of best fit with 95% CI shaded in grey. Black bars indicate median, within IQR boxes for EuroImmun/Roche/Abbott value. 
Red triangles indicate outliers, based on 1.5×IQR. TT3, Technical Transfer 3.









pen: first published as 10.1136/bm




9Robertson LJ, et al. BMJ Open 2021;11:e048142. doi:10.1136/bmjopen-2020-048142
Open access
the cohort provides a positive cohort for assessing assay 
sensitivity that includes individuals from the general 
public, healthcare workers and from convalescent plasma 
programmes. In the absence of a clear gold standard 
test, our system relies on no single test (each with their 
individual shortcomings) and instead takes an average of 
three. Our analysis of specificity on only pre- pandemic 
individuals (n=223) shows similar specificity (99.55%) to 
the larger mixed ‘known negative cohort’ (n=488, sensi-
tivity 99.59%). We also demonstrate a high level of analyt-
ical specificity of the AbC-19 test with no cross- reactivity 
against a panel of other respiratory viruses, including 
SARS- CoV-1 NL63 and 229E (online supplemental table 
4).
Our assessment of the AbC-19 LFIA in a laboratory 
setting, using characterised cohorts of known SARS- CoV-2 
antibody positive and antibody negative plasma, shows 
good performance metrics for its ability to detect 
SARS- CoV-2 IgG antibodies following natural infection. 
We note our use of plasma from venous blood samples, 
as opposed to a finger prick blood sample as would be 
used in rapid testing scenarios.27 Additionally, when the 
AbC-19 LFIA was used on our cohort, a number of the 
positive results scored low (1 of 10 using the scorecard 
under laboratory conditions, figure 3), with a faint test 
band visible to a trained laboratory scientist but perhaps 
difficult to identify as positive by individuals performing a 
single test (online supplemental figure 10). This faint line 
may be reflective of the longer time from infection for the 
Northern Ireland cohort used. If the AbC-19 LFIA is to be 
used in clinical settings, it is important to determine if all 
users observe the same results as observed in this labora-
tory evaluation.
This assessment of the AbC-19 LFIA does not provide 
data on how this test will perform in a seroprevalence 
screening scenario, but instead provides metrics for the 
performance of the test, where presence of SARS- CoV-2 
antibodies is of interest, as opposed to previous COVID-19 
infection. An important potential use of the AbC-19 LFIA 
would be in monitoring the immune response to vaccina-
tion, with most vaccines using SARS- CoV-2 spike protein 
antigens.34
CONCLUSION
We present a comprehensive analysis of pre- pandemic 
and two large pandemic cohorts (more than 700 individ-
uals) and in a longitudinal analysis, show that IgG anti-
bodies to SARS- CoV-2 antigens are detectable more than 
10 months from positive RT- qPCR test. We use antibody 
positive status as an alternative to RT- PCR- positive status 
as a standard for assessing SARS- CoV-2 antibody assays 
and show strong performance for the UK- RTC AbC-19 
LFIA rapid POC test in detecting SARS- CoV-2 antibodies. 
User experience in future studies in the real world is 
important and may alter the performance characteris-
tics. Also, the effect of operator training will have direct 
effects on test performance. We welcome further clinical 
evaluation of the AbC-19 LFIA in large cohorts of symp-
tomatic and asymptomatic individuals alongside large 
studies assessing vaccination outcomes in individuals to 
fully validate its implementation across all intended use 
cases.
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